Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine

Patent metadata

Field	Value
Publication number	US-10946089-B2
Application number	US-202016737969-A
Country	US
Kind code	B2
Filing date	Jan 9, 2020
Priority date	Aug 1, 2012
Publication date	Mar 16, 2021
Grant date	Mar 16, 2021

Abstract

Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.

First claim

The invention claimed is:

1. A recombinant modified vaccinia virus Ankara (MVA) comprising:
(a) at least one nucleotide sequence encoding an antigenic determinant of a respiratory syncytial virus (RSV) membrane glycoprotein, wherein the nucleotide sequence encodes an RSV F antigenic determinant;
(b) at least one nucleotide sequence comprising an open reading frame that encodes an RSV nucleocapsid antigenic determinant that is an RSV N nucleocapsid protein and an RSV nucleocapsid antigenic determinant that is an RSV M2 matrix protein;

and further comprising:
(c) at least one nucleotide sequence encoding an antigenic determinant of an RSV G membrane glycoprotein.

2. The recombinant MVA of claim 1 , wherein the nucleotide sequence in (a) encodes a full-length RSV F membrane glycoprotein.

3. The recombinant MVA of claim 1 , wherein the nucleotide in (a) is from RSV strain.

4. The recombinant MVA of claim 1 , wherein the nucleotide sequence in (a) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 6 or comprises the nucleotide sequence of SEQ ID NO: 5.

5. The recombinant MVA of claim 1 , wherein the nucleotide sequence in (b) encodes a full-length RSV N nucleocapsid protein and a full-length RSV M2 matrix protein.

6. The recombinant MVA of claim 1 , wherein the nucleotide sequence in (b) is from strain.

7. The recombinant MVA of claim 1 , wherein the nucleotide sequence in (b) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 35; or comprises the nucleotide sequence of SEQ ID NO: 34.

8. The recombinant MVA of claim 1 , wherein the nucleotide sequence in (b) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 10; or comprises the nucleotide sequence of SEQ ID NO: 9.

9. The recombinant MVA of claim 1 , wherein the nucleotide sequence in (b) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 33; or comprises the nucleotide sequence of SEQ ID NO: 32.

10. The recombinant MVA of claim 1 , wherein the nucleotide sequence in (b) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 14; or comprises the nucleotide sequence of SEQ ID NO: 13.

11. The recombinant MVA of claim 1 , wherein the nucleotide sequence in (b) further encodes a self-cleaving protease domain between the antigenic determinants of the RSV N nucleocapsid and the RSV M2 matrix proteins.

12. The recombinant MVA of claim 11 , wherein the nucleotide sequence in (c) encodes a full-length RSV G membrane glycoprotein.

13. The recombinant MVA of claim 12 , wherein the nucleotide sequence in (c) is from RSV strain A2.

14. The recombinant MVA of claim 13 , wherein the nucleotide sequence in (c) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2 or comprises the nucleotide sequence of SEQ ID NO: 1.

15. The recombinant MVA of claim 14 , wherein the MVA used for generating the recombinant MVA is MVA-BN deposited at the European Collection of Cell Cultures (ECACC) under number V00083008.

16. A pharmaceutical composition comprising the recombinant MVA of claim 1 .

17. A method for treating or preventing an RSV infection in a subject, comprising administering to the subject the recombinant modified vaccinia virus Ankara (MVA) of claim 1 .

18. The recombinant MVA of claim 11 , wherein the self-cleaving protease domain has the amino acid sequence set forth in SEQ ID NO:12.

Assignees

• Bavarian Nordic As

Inventors

• Cheminay Cédric
• Steigerwald Robin
• Chaplin Paul

Classifications

• C12Q1/70

  involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)} · CPC title

• C12Q1/6851

  Quantitative amplification · CPC title

• C12N2760/18522

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2710/24143

  viral genome or elements thereof as genetic vector · CPC title

• C12N2710/24121

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title